ConductScience.org, home

Paper40211010

Oroxylin A may promote cell apoptosis and inhibit epithelial-mesenchymal transition in endometrial cancer, associated with the ERβ/PI3K/AKT pathway.

Fan X and 8 others. Sci Rep, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Oroxylin A may promote cell apoptosis and inhibit epithelial-mesenchymal transition in endometrial cancer, associated with the ERβ/PI3K/AKT pathway. Papers, record 40211010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40211010

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Oroxylin A may promote cell apoptosis and inhibit epithelial-mesenchymal transition in endometrial cancer, associated with the ERβ/PI3K/AKT pathway.
PubMed
Journal
Sci Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
2.02, provisional
iCite
Revised in PubMed
2026-09-24
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fan XXue
2Wu LLuming
3Cheng TTong
4Lv WWeilong
5Tian JJiao
6Tao JJijun
7Tu SShiyan
8Tan FFangjun
9Wang YYiqing

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Epithelial-Mesenchymal TransitionMajor topic
ApoptosisMajor topic
FlavonoidsMajor topic
Proto-Oncogene Proteins c-aktMajor topic
Phosphatidylinositol 3-KinasesMajor topic
Endometrial NeoplasmsMajor topic
Signal TransductionMajor topic
Estrogen Receptor betaMajor topic
Female
Humans
Animals
Mice
Cell Line, Tumor
Mice, Nude
Mice, Inbred BALB C
Cell Proliferation
Xenograft Model Antitumor Assays
Cell Movement

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
24JRRA910the Science and Technology Program of Gansu ProvincePubMed

Source PubMed

Download CSV of grants

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136932403An integrated approach of network pharmacology, molecular docking, and experimental verification uncovers kaempferol as the effective modulator of HSD17B1 for treatment of endometrial cancer.J Transl Med2023https://conductscience.org/library/papers/36932403PubMed
232901849Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.Oncol Rep2020https://conductscience.org/library/papers/32901849PubMed
332512269ROS-dependent inhibition of the PI3K/Akt/mTOR signaling is required for Oroxylin A to exert anti-inflammatory activity in liver fibrosis.Int Immunopharmacol2020https://conductscience.org/library/papers/32512269PubMed
437714256Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.Cancer Lett2023https://conductscience.org/library/papers/37714256PubMed
536139025Oroxylin A: A Promising Flavonoid for Prevention and Treatment of Chronic Diseases.Biomolecules2022https://conductscience.org/library/papers/36139025PubMed
636214865Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.Naunyn Schmiedebergs Arch Pharmacol2023https://conductscience.org/library/papers/36214865PubMed
723922737An estrogen receptor dependent mechanism of Oroxylin A in the repression of inflammatory response.PLoS One2013https://conductscience.org/library/papers/23922737PubMed
834188177Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.Acta Pharmacol Sin2022https://conductscience.org/library/papers/34188177PubMed
923399685Involvement of estrogen receptor β5 in the progression of glioma.Brain Res2013https://conductscience.org/library/papers/23399685PubMed
1015941045Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography.J Chromatogr A2005https://conductscience.org/library/papers/15941045PubMed
1133535622The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer.Cells2021https://conductscience.org/library/papers/33535622PubMed
1231168597Picropodophyllin inhibits type I endometrial cancer cell proliferation via disruption of the PI3K/Akt pathway.Acta Biochim Biophys Sin (Shanghai)2019https://conductscience.org/library/papers/31168597PubMed
1330423148Molecular-targeted therapies and precision medicine for endometrial cancer.Jpn J Clin Oncol2019https://conductscience.org/library/papers/30423148PubMed
1423934681Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα.Int J Cancer2014https://conductscience.org/library/papers/23934681PubMed
1528726775Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression.Cell Death Dis2017https://conductscience.org/library/papers/28726775PubMed
1634117368Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression.Acta Pharmacol Sin2022https://conductscience.org/library/papers/34117368PubMed
1725100707Influence of AKT on progesterone action in endometrial diseases.Biol Reprod2014https://conductscience.org/library/papers/25100707PubMed
1831299894YAP promotes the malignancy of endometrial cancer cells via regulation of IL-6 and IL-11.Mol Med2019https://conductscience.org/library/papers/31299894PubMed
1937209937Saikosaponin D exerts cytotoxicity on human endometrial cancer ishikawa cells by inducing apoptosis and inhibiting metastasis through MAPK pathways.Food Chem Toxicol2023https://conductscience.org/library/papers/37209937PubMed
2030948788The molecular machinery of regulated cell death.Cell Res2019https://conductscience.org/library/papers/30948788PubMed

See all 35 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42194035Oroxylin A Directly Targets SRC to Inhibit the PI3K/AKT Signaling Axis in Pancreatic Cancer: An Integrated Bioinformatics and Experimental Study.Biomolecules2026https://conductscience.org/library/papers/42194035PubMed
42004947Astragaloside IV suppresses neuroinflammation via PI3K/Akt/NF-κB to ameliorate cerebral ischemia-reperfusion injury based on network pharmacology analysis and experimental validation.Front Immunol2026https://conductscience.org/library/papers/42004947PubMed
41743243Antitumor Effects of Apatinib on Tongue Cancer in Patient-Derived Xenograft Models.Iran J Med Sci2026https://conductscience.org/library/papers/41743243PubMed

Download CSV of cited by

Genes10

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40211010

GET https://conductscience.org/api/papers/v1/40211010/references?page=2